Jacek Jassem

13PUBLICATIONS
104CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersLiquid biopsiesOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 08, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

|Oct 24, 2025
TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent <i>TP53</i> mutations and FGFR pathway dysregulation.

Marcin Braun, Julia Sołek, Grzegorz Jan Stępień

|Dec 23, 2024
Impact of clinical factors on accuracy of ovarian cancer detection via platelet RNA profiling.

Maksym A Jopek, Michał Sieczczyński, Krzysztof Pastuszak

|Sep 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick

|Mar 29, 2024
Heterogeneity in precision oncology.

Bartłomiej Tomasik, Filip Garbicz, Marcin Braun

Pageof 3

Frequent Collaborators

3 joint publications

Anna J Żaczek

2 joint publications

Peter Schmid

2 joint publications

Michał Bieńkowski

2 joint publications

Kyung Hae Jung